Compounds > dabigatran
Page last updated: 2024-09-05

dabigatran and n(alpha)-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide

dabigatran has been researched along with n(alpha)-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide in 1 studies

Compound Research Comparison

Studies
(dabigatran)		Trials
(dabigatran)		Recent Studies (post-2010)
(dabigatran)		Studies
(n(alpha)-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide)		Trials
(n(alpha)-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide)		Recent Studies (post-2010) (n(alpha)-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide)
3,8872613,4905202

Protein Interaction Comparison

ProteinTaxonomydabigatran (IC50)n(alpha)-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide (IC50)
ProthrombinHomo sapiens (human)0.69
Trypsin-1Homo sapiens (human)0.169
Trypsin-2Homo sapiens (human)0.169
Trypsin-3Homo sapiens (human)0.169

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheng, K; Li, S; Liao, C; Lv, X; Tian, Y; Xiao, X; Xie, Z; Zhan, M1

Reviews

1 review(s) available for dabigatran and n(alpha)-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide

ArticleYear
The selectivity and bioavailability improvement of novel oral anticoagulants: An overview.
    European journal of medicinal chemistry, 2018, Feb-25, Volume: 146

    Topics: Administration, Oral; Anticoagulants; Biological Availability; Humans; Thromboembolism

2018